Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic
This study in France is for people aged 18-59 with Relapsing Remitting Multiple Sclerosis (RRMS). Researchers want to understand how different MS treatments affect the brain over time. They will compare newer, more effective treatments ("high-strength") with older, standard ones ("medium-strength"). They'll use MRI scans to measure brain shrinkage, which can be an important sign of how MS is progressing. Participants will also have blood tests and thinking/memory tests. The study aims to gather up-to-date information, as previous studies might not reflect current treatments. It’s a three-year study designed to help doctors better understand and manage MS for people like you.
At a glance
What is this study about?
This research wants to understand how Multiple Sclerosis (MS) affects people over time and how different treatments might change that. Specifically, it's looking at a type of MS called Relapsing Remitting MS (RRMS). Doctors have noticed that the way MS is managed has changed a lot recently, especially with the introduction of stronger medications about 10 years ago. Many people who weren't doing well on older, standard treatments are now stable with these newer, more effective ones. However, we don’t have enough long-term information from studies that include these new treatments.
This study will follow 400 people with RRMS over three years. The main goal is to compare how much the brain shrinks in people taking the stronger treatments verses those on standard treatments. Brain shrinkage, or 'brain atrophy', can be a silent way MS progresses, even when people feel well. By looking at MRI scans, blood tests, and special tests for thinking and memory, researchers hope to get a clearer picture of how these different treatments protect the brain and reduce the impact of MS.
Ultimately, the results from this study will help doctors make better decisions about which treatments are most effective in slowing down MS progression and improving the long-term well-being of people living with the condition. It also hopes to discover new ways to track MS progression that are more accurate and easier to use in everyday doctor visits.
Key takeaways
- Focuses on Relapsing Remitting MS (RRMS).
- Compares two types of MS treatments (standard vs. high-strength).
- Uses MRI scans to measure brain shrinkage over three years.
- Aims to improve understanding of long-term MS treatment effectiveness.
- No new medications are given; current treatments are observed.
- Requires commitment for three years of follow-up.
Who may be eligible?
To join this study, you need to be an adult between 18 and 59 years old who has Relapsing Remitting MS (RRMS). It's important that you haven't had an MS relapse (a flare-up of symptoms) for at least the last six months, and your MS shouldn't have been getting steadily worse.
You also need to be on a stable MS treatment – meaning you haven't changed your main MS medication in the past six months. You shouldn't have any medical reasons preventing you from having an MRI scan, like claustrophobia or a pacemaker. You also need to be able to commit to the study appointments over three years. Female participants must not be pregnant or breastfeeding.
People who have other types of MS, like Secondary Progressive MS or Primary Progressive MS, cannot join this particular study. Also, if you're unable to give your full written permission to take part, or if you're not covered by social security, you won't be able to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 18 and 59 years old?
- Do you have Relapsing Remitting MS (RRMS)?
- Have you been free of MS relapses for at least 6 months?
- Have you been on the same MS treatment for at least 6 months?
- Can you have an MRI scan (no pacemakers, severe claustrophobia, etc.)?
- Are you able to attend appointments over a three-year period?
What does participation involve?
If you join this study, you would be followed for three years. You'll have regular appointments where doctors will check your general health and how your MS is affecting you. You'll undergo MRI scans of your brain, which are important for measuring any changes over time. You will also have blood samples taken and complete special tests that check your thinking, memory, and other brain functions. The study aims to gather information about your existing MS medication, rather than prescribing new ones, as it compares how well current treatments are working. You would continue to take your prescribed MS treatment as usual, under the care of your existing doctors. The total duration of your active participation will be three years.
Potential risks and benefits
Locations (1)
- Neurology Department, Hopital Gui de ChauliacVerified postcodeMontpellier, France· Recruiting
Common questions
What type of MS are you focusing on?
This study is specifically looking at people with Relapsing Remitting Multiple Sclerosis (RRMS).
What will I have to do if I join?
You'll have regular MRI scans, blood tests, and thinking/memory tests over three years. You'll continue your current MS treatment.
Will I get a new MS treatment in this study?
No, this study observes how your current MS treatment influences your condition; it doesn't give you new or experimental drugs.
Why are you looking at brain shrinkage?
Brain shrinkage, or 'atrophy', is a way doctors can check how MS might be progressing, even when you feel okay. It helps us understand how well treatments are working to protect the brain.
How long will the study last for me?
If you participate, your involvement will be for a total of three years.
How to find out more
Xavier AYRIGNAC, Medical Doctor
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.